Payment overview · 2025
General Payments
$10,396.76
100 reported records · 15 companies
Healthcare provider profile · identity verified
Peter Stevens Fail, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Advanced Heart Failure and Transplant Cardiology · HOUMA, LA · NPI 1437156429
Verified facts
What the public records show
CMS Open Payments records show Peter Stevens Fail, MD received $10,396.76 in general payments during 2025 across 100 reported records.
Medtronic, Inc. accounted for 39.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Camzyos.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAMZYOS as an associated drug or biological on 41009 records involving 16400 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Camzyos by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 423 claims for Eliquis by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Verquvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 423 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYNDAMAX as an associated drug or biological on 1880 records involving 1527 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vyndamax by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$4,087.45 | 39.3% | 30 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $3,366.38 | 32.4% | 35 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,541.00 | 14.8% | 10 | 2025 |
| Ancora Heart, Inc. | Unresolved — no canonical attribution shown | $435.48 | 4.2% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $186.07 | 1.8% | 8 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $179.20 | 1.7% | 2 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $165.84 | 1.6% | 2 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $119.75 | 1.1% | 2 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $100.00 | 1.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $91.36 | 0.9% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $32.60 | 0.3% | 1 | 2025 |
| Cardiac Dimensions, Inc. | Unresolved — no canonical attribution shown | $30.51 | 0.3% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $24.25 | 0.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.49 | 0.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.38 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,227.38 | 74 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,050.00 | 12 |
| Travel and Lodging | $2,244.38 | 13 |
| Consulting Fee | $875.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $3,993.29 | 27 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $1,056.23 | 9 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $1,018.70 | 2 | 2025 |
Source payment records
|
|||||
| AccuCinch Normalized: accucinch |
Device | Ancora Heart, Inc. | $435.48 | 4 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $360.14 | 5 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $186.07 | 8 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $130.03 | 2 | 2025 |
Source payment records
|
|||||
| AZUR CX DETACHABLE Normalized: azur cx detachable |
Device | Terumo Medical Corporation | $104.78 | 1 | 2025 |
Source payment records
|
|||||
| R2P MISAGO Normalized: r2p misago |
Device | Terumo Medical Corporation | $104.78 | 1 | 2025 |
Source payment records
|
|||||
| RUBY Coil Normalized: ruby coil |
Device | Penumbra, Inc. | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| ANGIOVAC Normalized: angiovac |
Device | AngioDynamics, Inc. | $99.18 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $91.36 | 1 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $66.66 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $60.77 | 2 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $33.39 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $32.60 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER TALISMAN Normalized: amplatzer talisman |
Device | Abbott Laboratories | $32.13 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| TUBING KIT - STROKE Normalized: tubing kit stroke |
Device | Terumo Medical Corporation | $14.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAMZYOS camzyos |
2025 | Camzyos | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | CAMZYOS open payments reported associated product |
CMS Open Payments — General Payments 41009 supporting records · 16400 recipient NPIs · example record 1184377697 |
Camzyos · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
423 | 110 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
423 | 110 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | VYNDAMAX open payments reported associated product |
CMS Open Payments — General Payments 1880 supporting records · 1527 recipient NPIs · example record 1228795749 |
Vyndamax · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1295 | 362 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1278 | 376 |
| Metoprolol Succinate | Metoprolol Succinate | 1274 | 369 |
| Ezetimibe | Ezetimibe | 907 | 244 |
| Jardiance | Empagliflozin | 904 | 223 |
| Clopidogrel | Clopidogrel Bisulfate | 716 | 216 |
| Amlodipine Besylate | Amlodipine Besylate | 700 | 214 |
| Valsartan | Valsartan | 689 | 209 |
| Entresto | Sacubitril/Valsartan | 674 | 180 |
| Spironolactone | Spironolactone | 659 | 215 |
| Eliquis | Apixaban | 423 | 110 |
| Furosemide | Furosemide | 374 | 113 |
| Carvedilol | Carvedilol | 302 | 83 |
| Doxazosin Mesylate | Doxazosin Mesylate | 290 | 84 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 259 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 245 | 80 |
| Irbesartan | Irbesartan | 233 | 55 |
| Torsemide | Torsemide | 224 | 62 |
| Lisinopril | Lisinopril | 215 | 57 |
| Repatha Pushtronex | Evolocumab | 177 | 44 |
| Repatha Sureclick | Evolocumab | 172 | 46 |
| Losartan Potassium | Losartan Potassium | 171 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 48 |
| Farxiga | Dapagliflozin Propanediol | 143 | 50 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 140 | 33 |
| Warfarin Sodium | Warfarin Sodium | 132 | 29 |
| Amiodarone Hcl | Amiodarone Hcl | 129 | 42 |
| Xarelto | Rivaroxaban | 127 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 28 |
| Mupirocin | Mupirocin | 115 | 112 |
| Ranolazine Er | Ranolazine | 106 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 29 |
| Potassium Chloride | Potassium Chloride | 94 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 92 | 35 |
| Cilostazol | Cilostazol | 90 | 28 |
| Benazepril Hcl | Benazepril Hcl | 89 | 26 |
| Nifedipine Er | Nifedipine | 83 | 25 |
| Ramipril | Ramipril | 83 | 26 |
| Simvastatin | Simvastatin | 83 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 79 | 25 |
| Nitroglycerin | Nitroglycerin | 72 | 52 |
| Atenolol | Atenolol | 64 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 58 | 15 |
| Fenofibrate | Fenofibrate | 52 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 48 | 14 |
| Acebutolol Hcl | Acebutolol Hcl | 47 | 11 |
| Metolazone | Metolazone | 46 | 23 |
| Diltiazem 24hr Er | Diltiazem Hcl | 43 | 17 |
| Methylprednisolone | Methylprednisolone | 42 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | suppressed |
| Praluent Pen | Alirocumab | 38 | suppressed |
| Sotalol | Sotalol Hcl | 38 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | 11 |
| Alprazolam | Alprazolam | 34 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Omeprazole | Omeprazole | 31 | suppressed |
| Camzyos | Mavacamten | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 27 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 20 |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 22 | suppressed |
| Nadolol | Nadolol | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Verquvo | Vericiguat | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | 17 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 18 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Gabapentin | Gabapentin | 14 | suppressed |
| Matzim La | Diltiazem Hcl | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Vyndamax | Tafamidis | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $10,396.76 · 100 records | Medtronic, Inc. | ALPHAVAC, AMPLATZER AMULET, AMPLATZER TALISMAN, ANGIOVAC, AZUR CX DETACHABLE, AccuCinch, Assure WCD, CAMZYOS, COREVALVE EVOLUT R, EVKEEZA, EVOQUE, IN.PACT ADMIRAL, MITRACLIP, R2P MISAGO, REPATHA, RUBY Coil, SYMPLICITY G3, TRICLIP, TUBING KIT - STROKE, VYNDAQEL, WINREVAIR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Camzyos play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error